Structure of Vitexicarpin
CAS No.: 479-91-4
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Casticin is a methoxyflavone compound derived from Vitex agnus-castus with antimitotic and anti-inflammatory activities. Casticin inhibits the activation of STAT3.
Synonyms: Casticin
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 479-91-4 |
Formula : | C19H18O8 |
M.W : | 374.34 |
SMILES Code : | O=C1C(OC)=C(C2=CC=C(OC)C(O)=C2)OC3=C1C(O)=C(OC)C(OC)=C3 |
Synonyms : |
Casticin
|
MDL No. : | MFCD00210481 |
InChI Key : | PJQLSMYMOKWUJG-UHFFFAOYSA-N |
Pubchem ID : | 5315263 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
In Vitro:
Cell Line
|
Concentration | Treated Time | Description | References |
Human lung cancer A549 cells | 20 µM | 48 hours | Induced DNA damage, showing smeared DNA | Molecules. 2020 Jan 15;25(2):341 |
MC3T3-E1 cells | 0, 1, 2 µM | 7 and 21 days | Cas had no significant effect on MC3T3-E1 cells. | Int J Mol Med. 2023 May;51(5):43 |
Human lung cancer A549 cells | 20 µM | 0, 6, 12, 24, 48 hours | Assess cell viability, results showed a time-dependent reduction in viable cell numbers | Molecules. 2020 Jan 15;25(2):341 |
S18 cells | 0, 1, 2, 4 µM | 12 hours | To evaluate the effect of Vitexicarpin on the clonogenic ability of S18 cells, results showed that Vitexicarpin significantly reduced the clonogenic activity of S18 cells | Cancer Cell Int. 2019 Dec 21;19:348 |
Human lung cancer A549 cells | 20 µM | 12-48 hours | Induced chromatin condensation, showing lighter DAPI staining and higher fluorescent intensity | Molecules. 2020 Jan 15;25(2):341 |
Human lung cancer A549 cells | 20 µM | 24 and 48 hours | Induced DNA damage, resulting in the development of comet tails | Molecules. 2020 Jan 15;25(2):341 |
C666-1 cells | 0, 2, 4, 8 µM | 24 hours | To evaluate the effect of Vitexicarpin on the cell cycle of C666-1 cells, results showed that Vitexicarpin caused accumulation of cells in the G2/M phase in a dose-dependent manner | Cancer Cell Int. 2019 Dec 21;19:348 |
MC3T3-E1 pre-osteoblasts | 1, 5, 10 µM | 24 hours | Vitex was not as highly toxic to normal cells as the known anti-osteosarcoma drug Methotrexate | Int J Mol Sci. 2024 Mar 22;25(7):3582 |
C3H/10T1/2 mesenchymal stem cells (MSCs) | 1, 5, 10 µM | 24 hours | Vitex was not as highly toxic to normal cells as the known anti-osteosarcoma drug Methotrexate | Int J Mol Sci. 2024 Mar 22;25(7):3582 |
Human osteosarcoma SJSA1 cells | 1, 5, 10 µM | 24 hours | Vitex significantly reduced the viability of SJSA1 cells to a greater extent than that of MG63 cells | Int J Mol Sci. 2024 Mar 22;25(7):3582 |
Human osteosarcoma MG63 cells | 1, 5, 10 µM | 24 hours | Vitex significantly reduced the viability of MG63 cells and induced apoptosis as evidenced by the appearance of cleaved-PARP, cleaved-caspase 3 | Int J Mol Sci. 2024 Mar 22;25(7):3582 |
Human myeloma RPMI 8226 cells | 5 µM | 24 hours | CTC significantly inhibited the survival and proliferation of RPMI 8226 cells with an IC50 value of 6 µM. | Cancers (Basel). 2019 Feb 22;11(2):254 |
Human gastric cancer SNU16 cells | 5 µM | 24 hours | CTC significantly inhibited the survival and proliferation of SNU16 cells with an IC50 value of 7 µM. | Cancers (Basel). 2019 Feb 22;11(2):254 |
Human breast cancer MCF-7 cells | 5 µM | 24 hours | CTC significantly inhibited the survival and proliferation of MCF-7 cells with an IC50 value of 8.5 µM. | Cancers (Basel). 2019 Feb 22;11(2):254 |
BEAS-2B cells | 5–20 µM | 24 hours | Casticin significantly reduced the levels of CCL5, MCP-1, IL-6, and IL-8 in TNF-α-stimulated BEAS-2B cells. In BEAS-2B cells stimulated with IL-4 and TNF-α, casticin significantly attenuated the levels of CCL11, CCL24, and CCL26. | Front Pharmacol. 2018 Jun 14;9:635 |
4T1 cells | 0.25 and 0.50 µM | 24 hours | To investigate the effects of Vitexicarpin on breast cancer cell migration and invasion, results showed that Vitexicarpin significantly inhibited the migration and invasion of 4T1 cells. | Biosci Rep. 2018 Nov 30;38(6):BSR20180738 |
MDA-MB-231 cells | 0.25 and 0.50 µM | 24 hours | To investigate the effects of Vitexicarpin on breast cancer cell migration and invasion, results showed that Vitexicarpin significantly inhibited the migration and invasion of MDA-MB-231 cells. | Biosci Rep. 2018 Nov 30;38(6):BSR20180738 |
Hep G2 cells | 3.0, 10.0, 30.0 µM | 24 hours | To investigate the inhibitory effect of Vitexicarpin on the growth of hepatocellular carcinoma cells, results showed that Vitexicarpin significantly inhibited the growth of Hep G2 cells with an IC50 of 13.6 μmol/L | World J Gastroenterol. 2011 Oct 14;17(38):4298-307 |
PLC/PRF/5 cells | 3.0, 10.0, 30.0 µM | 24 hours | To investigate the inhibitory effect of Vitexicarpin on the growth of hepatocellular carcinoma cells, results showed that Vitexicarpin significantly inhibited the growth of PLC/PRF/5 cells with an IC50 of 9.4 μmol/L | World J Gastroenterol. 2011 Oct 14;17(38):4298-307 |
A375.S2 human melanoma cells | 100-200 nM | 24 hours | To investigate the effect of Vitexicarpin on the migration and invasion of A375.S2 cells, results showed that Vitexicarpin significantly inhibited cell migration and invasion, and reduced the expression of MMP-2 and MMP-1. | Molecules. 2016 Mar 19;21(3):384 |
NPC cell lines 5-8F | 0, 1, 2, 4, 8 µM | 24, 48, 72 hours | To evaluate the effect of Vitexicarpin on the growth of NPC cells, results showed that Vitexicarpin decreased the viability of NPC cell lines in a concentration-dependent manner | Cancer Cell Int. 2019 Dec 21;19:348 |
293T cells | 0, 0.1, 0.5, 1, 4, 7, 10 µM | 24, 48, 72 hours | Evaluate cell viability, results showed that casticin did not significantly inhibit 293T cell viability. | Cancer Cell Int. 2017 Jan 5;17:9 |
SGC996 cells | 0, 0.1, 0.5, 1, 4, 7, 10 µM | 24, 48, 72 hours | Evaluate cell viability, results showed that casticin significantly inhibited gallbladder cancer cell proliferation in a dose- and time-dependent manner. | Cancer Cell Int. 2017 Jan 5;17:9 |
NOZ cells | 0, 0.1, 0.5, 1, 4, 7, 10 µM | 24, 48, 72 hours | Evaluate cell viability, results showed that casticin significantly inhibited gallbladder cancer cell proliferation in a dose- and time-dependent manner. | Cancer Cell Int. 2017 Jan 5;17:9 |
Rat pituitary cells | 0.01, 0.1, 1, 10 µM | 48 hours | To investigate the effects of Vitexicarpin on E2-stimulated pituitary cell proliferation and prolactin release. Results showed that Vitexicarpin significantly inhibited E2-induced pituitary cell proliferation and prolactin release. | Acta Pharmacol Sin. 2010 Dec;31(12):1564-8 |
Human lung cancer A549 cells | 0, 10, 20, 30, 40, 50 µM | 48 hours | Assess cell viability, results showed a concentration-dependent reduction in viable cell numbers | Molecules. 2020 Jan 15;25(2):341 |
MCF-7 cells | 25.8 µM | 48 hours | Evaluated antiproliferative potential, results showed IC50 value of FLV2 against MCF-7 cells was 25.8 μM | Saudi Pharm J. 2022 Sep;30(9):1301-1314 |
HepG2 cells | 23.9 µM | 48 hours | Evaluated antiproliferative potential, results showed IC50 value of FLV2 against HepG2 cells was 23.9 μM | Saudi Pharm J. 2022 Sep;30(9):1301-1314 |
Bone marrow-derived macrophages (BMMs) | 0, 0.5, 1, 1.5, 2 µM | 5-7 days | Cas inhibited RANKL-induced osteoclast differentiation in a concentration-dependent manner, with particularly pronounced effects at 2 µM. | Int J Mol Med. 2023 May;51(5):43 |
MCF-7 cells | 3.1 µM | 6 days | To evaluate the estrogen-like activity of Vitexicarpin on MCF-7 cells. Results showed that Vitexicarpin significantly increased MCF-7 cell proliferation at low concentrations, and this effect was completely attenuated by the ER antagonist ICI 182,780. | Biomolecules. 2021 Jul 16;11(7):1033 |
In Vivo:
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
Balb/c mice | Breast cancer lung metastasis model | Intraperitoneal injection | 10 mg/kg | Once every 2 days for 4 weeks | To investigate the effects of Vitexicarpin on breast cancer cell lung metastasis, results showed that Vitexicarpin significantly reduced the number of lung metastatic nodules. | Biosci Rep. 2018 Nov 30;38(6):BSR20180738 |
Nude mice | NOZ cell xenograft model | Intraperitoneal injection | 10, 20 mg/kg | Every 2 days for 25 days | Evaluate the anti-tumor effect of casticin in vivo, results showed that casticin inhibited tumor growth in a dose-dependent manner. | Cancer Cell Int. 2017 Jan 5;17:9 |
Sprague Dawley (SD) rats | Metoclopramide dihydrochloride-induced hyperprolactinemia (MIHP) model | Intraperitoneal injection | 10, 20, 40 mg/kg | Once daily for 7 days | To investigate the effects of Vitexicarpin on serum prolactin levels in hyperprolactinemic rats. Results showed that Vitexicarpin significantly reduced serum prolactin levels. | Acta Pharmacol Sin. 2010 Dec;31(12):1564-8 |
Wistar rats | Chronic obstructive pulmonary disease model | Subcutaneous injection | 10, 20, and 30 mg/kg | Twice daily for 12 weeks | CST significantly improved lung function, reduced white blood cells, neutrophils, and macrophages in BALF, restored plasma leptin and C-reactive protein levels, and inhibited the NF-?B and iNOS pathway. | Drug Des Devel Ther. 2020 Nov 17;14:5019-5027 |
C57BL/6 female mice | Ovariectomy (OVX)-induced osteoporosis model | Intraperitoneal injection | 2.5 mg/kg and 5 mg/kg | Once every 2 days for 42 consecutive days | Cas significantly reduced bone loss and osteoclast activity in ovariectomized mice by inhibiting the AKT/ERK and NF-κB signaling pathways. | Int J Mol Med. 2023 May;51(5):43 |
Nude mice | Xenograft mouse model | Intraperitoneal injection | 40 mg/kg | Once daily for 12 days | To evaluate the inhibitory effect of Vitexicarpin on tumour growth in vivo, results showed that Vitexicarpin significantly inhibited tumour growth | Cancer Cell Int. 2019 Dec 21;19:348 |
Female BALB/c mice | OVA-induced asthma model | Intraperitoneal injection | 5 or 10 mg/kg | Administered 1 h before OVA challenge or methacholine inhalation, continued until the end of the experiment | Casticin significantly reduced airway hyper-responsiveness (AHR), goblet cell hyperplasia, and oxidative responses in the lungs of asthmatic mice. Mechanistic studies revealed that casticin attenuated the levels of Th2 cytokine in bronchoalveolar lavage fluids and regulated the expression of Th2 cytokine and chemokine genes in the lung. Casticin also significantly regulated oxidative stress and reduced inflammation in the lungs of mice with asthma. | Front Pharmacol. 2018 Jun 14;9:635 |
Tags: Casticin | Vitexicarpin | STAT | inhibitor | 479-91-4 |
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL